This paper is in the following e-collection/theme issue:

#xEndocrinology (6) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (217) Diabetes (267) Diabetes Self-Management (598) Obesity (119) Innovative Methods in Public Health and Surveillance (392) Decision Support for Health Professionals (1569)

Published on in Vol 5 (2024)

Preprints (earlier versions) of this paper are available at https://www.medrxiv.org/content/10.1101/2023.11.19.23298750v1, first published .
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

Authors of this article:

Tigran Makunts1 Author Orcid Image ;   Haroutyun Joulfayan2 Author Orcid Image ;   Ruben Abagyan1 Author Orcid Image
Article Authors Cited by (8) Tweetations (7) Metrics

Journals

  1. Makunts T, Joulfayan H, Abagyan R. Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”. JMIRx Med 2024;5:e58273 View
  2. . Peer Review for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”. JMIRx Med 2024;5:e59120 View
  3. Torbahn G, Lischka J, Brown T, Ells L, Kelly A, Wabitsch M, Weghuber D. Anti‐Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps. Clinical Endocrinology 2025;102(1):51 View
  4. Kelly C, Sipos J. Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists. The Journal of Clinical Endocrinology & Metabolism 2025;110(6):e2080 View
  5. Humaida S, Manzalji K, Seyam N, Al-Masalmani L. Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use. Cureus 2025 View
  6. Pollack R, Stokar J. Long‐Term Glucagon‐Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes. Diabetes/Metabolism Research and Reviews 2025;41(8) View
  7. Iuliano S, Mirabelli M, Giuliano S, Brunetti A. Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer. Current Opinion in Oncology 2025 View
  8. Khela H, Kishan A, Manriquez A, Kirby L, Chisango Z, Carayannopoulos N, Singh M, Cottrill E, Avedian R, Kleck C, Shaffrey C, Schoenfeld A, Eward W, Passias P, Daniels A, Jankowski P. Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist Use on Short-Term and Long-Term Outcomes Following Thoracic and/or Lumbar Fusion for Spinal Deformity: A BMI-Stratified Cohort Study. Spine Open 2026;2(1) View